| Type | Sym | Class | Transaction | Value $ | Shares | Change % | * Price $ | Shares After | Date | Ownership | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|
| transaction | CEMI | Common Stock | Options Exercise | +16.3K | +18.1% | 106K | Jun 24, 2021 | Direct | F1 | ||
| transaction | CEMI | Common Stock | Disposition pursuant to a tender of shares in a change of control transaction | -$47.9K | -106K | -100% | $0.45 | 0 | Apr 26, 2023 | Direct | F2 |
| Type | Sym | Class | Transaction | Value $ | Shares | Change % | * Price $ | Shares After | Date | Underlying Class | Amount | Exercise Price | Ownership | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| transaction | CEMI | Restricted stock units | Options Exercise | $0 | -16.3K | -100% | $0.00* | 0 | Jun 24, 2021 | Common stock | 16.3K | Direct | F1, F3 | |
| transaction | CEMI | Restricted stock units | Disposed to Issuer | -32K | -100% | 0 | Apr 27, 2023 | Common stock | 32K | Direct | F2, F4 | |||
| transaction | CEMI | Nonqualified stock options | Disposed to Issuer | -36.3K | -100% | 0 | Apr 27, 2023 | Common stock | 36.3K | $2.36 | Direct | F5 | ||
| transaction | CEMI | Nonqualified stock options | Disposed to Issuer | -41.1K | -100% | 0 | Apr 27, 2023 | Common stock | 41.1K | $1.25 | Direct | F5 |
Katherine Lyon Davis is no longer subject to Section 16 filing requirements. Form 4 or Form 5 obligations may continue.
| Id | Content |
|---|---|
| F1 | Each restricted stock unit represents a contingent right to receive one share of common stock. |
| F2 | Reflects disposition of Issuer common stock in connection with the consummation of the transactions contemplated by the Agreement and Plan of Merger, dated January 31, 2023 (the "Merger Agreement"), by and among the Issuer, Biosynex SA ("Parent"), and Project Merci Merger Sub, Inc. ("Purchaser"), including the completion on April 26, 2023 of a tender offer to purchase all of the outstanding shares of Issuer common stock at a price of $0.45 per share in cash, without interest (the "Offer Price"), and the consummation of the merger (the "Merger") between the Issuer and Purchaser on April 27, 2023. Pursuant to the Merger Agreement, as of the effective time of the Merger (the "Effective Time"), each outstanding share of Issuer common stock was cancelled in exchange for the right to receive an amount equal to the Offer Price. |
| F3 | On March 16, 2020, the Reporting person was granted 16,314 restricted stock units which vested in full immediately prior to the earlier to occur of (i) the 2021 annual meeting of stockholders of the issuer, and (ii) a Change in Control (as defined in the 2019 Omnibus Incentive Plan of the issuer). |
| F4 | Each Company RSU (as defined in the Merger Agreement) that was outstanding as of immediately prior to the Effective Time was cancelled and converted into the right to receive an amount in cash equal to the product of (a) the total number of Shares (as defined the Merger Agreement) issuable in settlement of such Company RSU immediately prior to the Effective Time without regard to vesting multiplied by (b) the Merger Consideration (as defined in the Merger Agreement). |
| F5 | As of the Effective Time, by virtue of the Merger and without any further action on the part of the holders thereof, Parent, Purchaser or the Issuer, each option which had a per share exercise price that is equal to or more than the Offer Price (each, an "Out of the Money Option") that was then outstanding and unexercised as of immediately before the Effective Time was cancelled at the Effective Time without any consideration payable therefor. |